Officials Visit Shenzhen True Flavor Biotech for Industry Research

Aug.08.2022
Officials Visit Shenzhen True Flavor Biotech for Industry Research
Shenzhen officials visit Shenzhen Zhenwei Bioscience to discuss their development plans and commend their innovative progress.

On August 4th, a delegation led by Cai Ying, Secretary of the Guangming District Committee in Shenzhen, including Shen Huaxin and Zhang Feng, both members of the District Committee, visited Shenzhen Truly Bio-Tech Co., Ltd. They were accompanied by Peng Hua, Deputy Director of the District Committee and Government Office, Lin Shuping, Director of the District Industrial and Information Bureau, Liu Kun, Secretary of the Yutang Street Party Working Committee, Liu Li, Deputy Director of the District Investment Promotion Service Center, and Zeng Peisheng, Deputy Director of the Guangming District Tobacco Monopoly Bureau. The general manager of Truly Bio-Tech, Zou Yang, and other members of management welcomed and hosted the delegation.


A research team conducted a site visit to the offices of Truly Flavored Biotech and received a detailed explanation from the company's leader on various aspects of the company's functional centers, including the introduction of top research equipment, the standardization of process systems, the improvement of talent, and the upgrading of industry intelligence. The team also observed the operation of the Aerosol Technology Research Institute, the pharmaceutical-grade GMP cleanroom, the quality control center, and the fragrance development center, gaining a thorough understanding of the current state of technology personnel, hardware and software facilities, and product development progress. The team engaged in in-depth discussions with staff members and gained a comprehensive understanding of the processes involved in raw material selection, quality testing, and new product research and development. The team fully recognized Truly Flavored Biotech's efforts to "promote innovation-led industry and drive development with scientific research" as a benchmark, a growth booster, and a long-term strategy.


After the visit, a symposium was held under the chairmanship of the Huanxin Executive Committee of the research group.


During the symposium, Secretary Cai Ying fully recognized the work of Zhenwei Biology. She pointed out that as a leading company in the electronic atomized liquid industry, Zhenwei Biology not only has a strong development momentum, but also actively undertakes corporate social responsibility. The company is also forward-thinking in research and innovation, market judgment, and new enterprise layout. At the same time, Secretary Cai Ying expressed deep concern for the company's future development plan. She hopes that Zhenwei Biology will further improve its industrial layout, seize opportunities for further development and expansion, and integrate into the overall development of the Guangming Science City. Meanwhile, the government and various departments of Guangming District will continue to implement pro-enterprise and supportive policies, providing top-notch services and quality space for long-term development and stability of enterprises. The government aims to maintain the vitality of the market, job security, and the welfare of the people in promoting the steady and progressive development of the local economy.


During the meeting, the research team listened to a report from Mr. Zou Yang, the General Manager of Zhenwei Biotech, on the progress and achievements of the company's phase work and the strategic planning for future development. Mr. Zou focused on the current national policies for the electronic atomized liquid industry, Zhenwei's development of new products in compliance with national standards, and the company's economic growth in the first half of the year. He stated that with the help of preferential policies from the government and various departments in Guangming District, Zhenwei Biotech's economic growth has been rapidly increasing since the first half of 2022. Furthermore, in order to better implement industry policy requirements, Zhenwei Biotech established the Zhenwei Biotech (Yunnan) Research Institute immediately after obtaining the tobacco monopoly production license, and is fully engaged in the research of tobacco-flavored atomized products. Zhenwei Biotech hopes to cooperate with the industry's upstream and downstream industries to create electronic atomized products with international influence.


The General Manager, Zou Yang, also stated that Zhenwei Biology will establish itself in Guangming, adhere to the real economy, persist in innovation, elevate its standards, strive to improve the company's efficiency and size, and firmly uphold the industry mission of "being a role model, setting an example, and leading the way." With a foundation in the electronic atomization liquid industry, they will develop in multiple modes, channels, and diversify cooperation, continuously improve market confidence with new development and achievements, make greater contributions to socio-economic development, and also hope that Zhenwei Biology will rely on its strong scientific research capabilities to make a positive contribution to the economic development of Guangming district.


The visit by district leaders is a strong recognition of the achievements in our company's development. In the future, Zhenwei Biological will proactively embrace regulation, adhere to industry policy requirements and government calls, increase research and development investment, and persist in pursuing high-quality development. We will contribute to the economic development of Guangming District and create a win-win outcome.


This article contains excerpts or reprints from third-party sources whose copyrights belong to the original media and authors. If there is any infringement, please contact us for deletion. Any individual or organization that wants to reprint this content should contact the author and refrain from direct reposting.


This document has been generated through artificial intelligence translation and is provided solely for the purposes of industry discourse and learning. Please note that the intellectual property rights of the content belong to the original media source or author. Owing to certain limitations in the translation process, there may be discrepancies between the translated text and the original content. We recommend referring to the original source for complete accuracy. In case of any inaccuracies, we invite you to reach out to us with corrections. If you believe any content has infringed upon your rights, please contact us immediately for its removal.

Al Fakher Enters the Oral Nicotine Market With Four Flavors
Al Fakher Enters the Oral Nicotine Market With Four Flavors
Al Fakher has launched nicotine pouches, marking the world’s leading hookah brand’s entry into the modern oral nicotine category.
Apr.01 by 2FIRSTS.ai
Russian Vape Industry Proposes State Monopoly on E-Liquid Production as Alternative to Ban
Russian Vape Industry Proposes State Monopoly on E-Liquid Production as Alternative to Ban
Russian business groups are trying to persuade the authorities to abandon plans to ban the sale of e-cigarettes and related liquids at both the federal and regional levels.
Apr.03 by 2FIRSTS.ai
Thai Vape User Numbers Rose More Than 11-Fold in Three Years, Group Says Ban Should Be Reassessed
Thai Vape User Numbers Rose More Than 11-Fold in Three Years, Group Says Ban Should Be Reassessed
A network of e-cigarette users in Thailand has urged the new government to review the country’s vape ban, saying official data show that use has risen sharply despite more than a decade of prohibition.
Mar.27 by 2FIRSTS.ai
Fifth Circuit Hears Challenge to FDA’s Standard for Reviewing Flavored Vape Applications
Fifth Circuit Hears Challenge to FDA’s Standard for Reviewing Flavored Vape Applications
A three-judge panel of the U.S. Court of Appeals for the Fifth Circuit heard oral arguments on Tuesday in a case brought by seven small vape-liquid companies challenging the Food and Drug Administration’s denial of marketing authorization for their flavored electronic nicotine products.
Apr.30 by 2FIRSTS.ai
Imperial Brands Pulls myblu Vape Business From U.S., Citing Prolonged FDA Approval Process
Imperial Brands Pulls myblu Vape Business From U.S., Citing Prolonged FDA Approval Process
Imperial Brands said it will phase out its myblu vaping business in the United States, citing prolonged FDA approval timelines for new vape products. The company said it will instead focus on modern oral nicotine products in the U.S., including the expansion of its Zone brand and new flavors. While overall next-generation product revenue continued to grow, revenue from the category in the Americas declined sharply.
May.12
FDA and NIH Release New Wave 8 Restricted-Use PATH Study Data Files
FDA and NIH Release New Wave 8 Restricted-Use PATH Study Data Files
FDA’s Center for Tobacco Products and NIH’s National Institute on Drug Abuse announced that new Wave 8 restricted-use data files from the PATH Study are now available. The files contain data collected between January 2024 and December 2024, including questionnaire data, location characteristics data, and state identifier data.
Apr.17 by 2FIRSTS.ai